MicroRNAs and other non-coding RNAs as targets for anticancer drug development

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are key non-coding RNAs involved in cancer development.
• miRNA therapeutics, like the first cancer-targeted drug MRX34, are gaining significant research and industry interest.
• The roles and therapeutic potential of lncRNAs in cancer are increasingly recognized.

Purpose of the Study:

• To review the involvement of miRNAs and lncRNAs in various cancers.
• To summarize novel mechanisms of action for these non-coding RNAs in cancer.
• To discuss current strategies and challenges in developing ncRNA-targeting cancer therapeutics.

Main Methods:

• Literature review of scientific publications on miRNAs, lncRNAs, and cancer therapeutics.
• Analysis of clinical trial data for miRNA-based drugs.
• Synthesis of information on ncRNA mechanisms and therapeutic design.

Main Results:

• The first miRNA-based cancer therapeutic (MRX34) has entered Phase I clinical trials.
• Emerging evidence highlights diverse roles of lncRNAs in oncogenesis.
• Novel mechanisms of action for both miRNAs and lncRNAs in cancer are being uncovered.

Conclusions:

• miRNA and lncRNA therapeutics represent a promising frontier in cancer treatment.
• Understanding the complex roles and mechanisms of ncRNAs is crucial for effective drug design.
• Overcoming challenges in ncRNA-based therapeutic development is essential for clinical success.